welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies
study id #: NCT02109692
condition: Muscular Dystrophies, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD), caused by mutations in the DMD gene, is the most common and most severe progressive dystrophy of the child. Although the development is rapidly progressive, there is variability in the severity of the disease between DMD patients that do not correlate with the type of mutations in the DMD gene. There are no easily measurable biomarkers for monitoring the DMD or moderate form of the disease, Becker muscular dystrophy (BMD). MicroRNAs (miRNAs) are involved in most cellular processes, and their expression pattern is a signature of the state of a cell. They represent a potential class of diagnostic and prognostic biomarkers. Some are specific for the skeletal myogenesis, and changes in their pattern of expression are associated with muscle diseases including muscular dystrophy. The levels of muscle- specific miRNAs are indeed greatly increased in the serum of DMD and BMD compared to control patients. The main objective of this is to validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects). Secondary objectives are i) to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy (DMD vs BMD) and also the progression of the disease (longitudinal study), ii) to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy), iii) to test candidate miRNAs recently identified but not yet analyzed in the serum of patients. Clinical data and samples will be recorded at each regular consultation. miRNA levels will be quantified using Real Time Quantitative RT-PCR.
intervention: blood sample
mechanism of action: No pharmaceutical intervention
last updated: February 04, 2020
start date: May 19, 2014
estimated completion: November 2018
phase of development: N/A
size / enrollment: 186
- Quantity of serum muscle-derived microRNAs of DMD patients [Time Frame: up to 12 months]
To validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects)
- severity of the dystrophinopathy [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy
- progression of the disease [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the progression of the disease
- specificitiy of miRNA for distrophinopathy [Time Frame: up to 36 months]
to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy)
• Eligible Sexes: all
• Patient suffers from dystrophinopathy or other muscle dystrophy
• Healthy volunteers
• signed informed consent
• social insurance
• patients or parents have not signed the informed consent
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With ...Background: - Children with Duchenne/Bec...
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
Analysis of a Virtual Reality Task in Patients With Duchenne Muscular DystrophyThe task consists in reach as much bubbl...
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
Use of Dynamic Arm Supports to Promote Activities of Daily Living in Individuals With DMDThis study is a longitudinal, randomized...
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trialsNovo Biosciences Inc., has achieved seve...
DMD clinical therapies II: P.133 The burden of participation in a clinical trial for boys with Duchenne muscular dys...Despite some medical breakthroughs in Du...